Skip to main content
SpringerLink
Log in

Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objectives

The aim of this work was to investigate the efficacy and safety of loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) undergoing elective percutaneous coronary intervention (PCI).

Methods

A total of 126 patients (≥70 years old) with NSTEACS were randomly divided into two groups: (1) loading-dose rosuvastatin-treated group, treated with rosuvastatin 20 mg 12 h prior to PCI, with a second dose administered just before PCI (n = 62), and (2) control-treated group, treated with the standard method according to ACC/AHA guidelines in UAP/NSTEMI 2007 (n = 64). All patients were required to take rosuvastatin 10 mg once a day starting 24 h after the surgery irrespective of the initial randomization assignment. The serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLox-1), high-sensitivity C-reactive protein (hs-CRP), creatinine kinase (CK)-MB, cardiac troponin I (cTnI), and brain natriuretic peptide (BNP) levels were measured prior to PCI and at 24 h and 30 days after PCI in both groups. The left ventricular ejection fraction (LVEF) levels were recorded prior to PCI and 30 days after PCI in both groups.

Results

Compared to pre-PCI, the serum sLox-1, hs-CRP, CK-MB, and cTnI levels were increased at 24 h after PCI (all p < 0.05) in both groups. However, the increased sLox-1, hs-CRP, CK-MB, and cTnI values were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group (p < 0.05). In addition the serum sLox-1 and hs-CRP levels were lower in the loading-dose rosuvastatin-treated group than in the control-treated group at 30 days after PCI. However, the decreased values of sLox-1and hs-CRP from 24 h after PCI to 30 days after PCI did not show any significant difference between the two groups. No significant difference was found in the serum ALT and Scr levels between the two groups before and after PCI. Compared to the control-treated group, the serum BNP level decreased (p < 0.05) and LVEF (p < 0.05) increased in the loading-dose rosuvastatin-treated group at 30 days after PCI.

Conclusion

The loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum hs-CRP, sLox-1, CK-MB, and cTnI levels, reduce myocardial injury and inflammatory reaction caused by PCI, and improve the LVEF level at 30 days after PCI, ensuring an effective and safe therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Qie E, Aukrust P. Atherosclerotic plaque stability-what dertermines the fate of a plaque? Prog Cardiovasc Dis. 2008;51:183–94.

    Article  PubMed  CAS  Google Scholar 

  2. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damge During Angioplasty Randomized Trial. J Am Coll Cardiol. 2009;54:566–8.

    Article  CAS  Google Scholar 

  3. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meriç M, Ağaç MT. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988–9.

    Article  PubMed  Google Scholar 

  4. Dunn S, Vohra RS, Murphy JE, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. The lectin-like oxidized low-density lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J. 2008;409:349–55.

    Article  PubMed  CAS  Google Scholar 

  5. Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY, Mehta JL, Beller GA, Glover DK, Meyer CH. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor Lox-1 using SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010;3:464–72.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Rajesh Kumar G, Mrudula Spurthi K, Kishore Kumar G, Mohanalatha K, Saraswati M, Mohini Aiyengar T, Chiranjeevi P, Srilatha Reddy G, Nivas S, Kaushik P, Sanjib Sahu K, Surekha Rani H. Evaluation of Hs-CRP Levels and Interleukin 18 (-137G/C) promoter polymorphism in risk prediction of coronary artery disease in first degree relatives. PLoS One. 2015;10:e0120359.

    Google Scholar 

  7. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401–8.

    Article  PubMed  CAS  Google Scholar 

  8. Cohen M, Diez JE, Levine GN, Ferguson JJ 3rd, Morrow DA, Rao SV, Zidar JP, ACC, AHA. Pharmacoinvasive management of acute coronary syndrome: incorporating the ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report-III. J Invasive Cardiol. 2007;2007(19):525–38.

    Google Scholar 

  9. Thorstensen A, Dalen H, Hala P, et al. Three-dimensional echocardiography in the evaluation of global and regional function in patients with recent myocardial infarction: a comparison with magnetic resonance imaging. Echocardiography. 2013;30:682–92.

    Article  PubMed  Google Scholar 

  10. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM, SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Prognostic significance of elevated troponin-1 after percutancous coronary intervention. J Am Coll Cardiol. 2002;39:1738–44.

    Article  PubMed  CAS  Google Scholar 

  11. Loannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol. 2003;42:1406–11.

    Article  CAS  Google Scholar 

  12. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA—ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–8.

    Article  PubMed  CAS  Google Scholar 

  13. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim NH, Ahn YK, Jeong JW. Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome. Heart Vessels. 2009;24:175–80.

    Article  PubMed  Google Scholar 

  14. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–7.

    Article  PubMed  CAS  Google Scholar 

  15. Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317–31.

    Article  PubMed  CAS  Google Scholar 

  16. Yan M, Mehta JL, Zhang W, Hu C. LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther. 2011;25:451–9.

    Article  PubMed  CAS  Google Scholar 

  17. Shih HH, Zhang S, Cao W, Hahn A, Wang J, Paulsen JE, Harnish DC. CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol. 2009;296:H1643–50.

    Article  PubMed  CAS  Google Scholar 

  18. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L. Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive protein-evoked endothelial vasodilator dysfunction in coronary arterioles. Circ Res. 2014;114:92–100.

    Article  PubMed  CAS  Google Scholar 

  19. Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis? Cardiovasc Drug Rev. 2007;25:146–61.

    Article  PubMed  CAS  Google Scholar 

  20. Kang BY, Mehta JL. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther. 2009;14:283–91.

    Article  PubMed  CAS  Google Scholar 

  21. Carter NJ. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Am J Cardiovasc Drugs. 2010;10:383–400.

    Article  PubMed  CAS  Google Scholar 

  22. Arnan MK, Burke GL, Bushnell C. Secondary prevention of stroke in the elderly: focus on drug therapy. Drugs Aging. 2014;31:721–30.

    Article  PubMed  CAS  Google Scholar 

  23. Dixon DL, Donohoe KL, Ogbonna KC, Barden SM. Current drug treatment of hyperlipidemia in older adults. Drugs Aging. 2015;32:127–38.

    Article  PubMed  Google Scholar 

  24. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin: the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57:1666–75.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 30070300). The authors acknowledge Dr. Wei Li and Dr. Xiaochen Yuan for their work support in clinical data record.

Author information

Authors and Affiliations

  1. Department of Cardiology, Institute of Cardiovascular Disease, Zhongda Hospital of Southeast University Medical School, Southeast University, Nanjing, 210000, China

    Yungen Jiao & Naifeng Liu

  2. Department of Cardiology, First People’s Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China

    Yungen Jiao, Feng Hu, Zhengang Zhang, Kaizheng Gong, Xiaoning Sun & Aihua Li

Authors
  1. Yungen Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhengang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaizheng Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoning Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aihua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naifeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naifeng Liu.

Ethics declarations

Conflicts of interest

YJ, FH, ZZ, KG, XS, AL and NL declare that there are no conflicts of interest directly relevant to the content of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiao, Y., Hu, F., Zhang, Z. et al. Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention. Clin Drug Investig 35, 777–784 (2015). https://doi.org/10.1007/s40261-015-0335-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-015-0335-1

Keywords

Search

Navigation